What Suvartar H Treats: Main Uses and Benefits

Suvartar H, containing Valsartan and Hydrochlorothiazide, is an antihypertensive medication used in situations involving elevated blood pressure. It is indicated for the treatment of hypertension to help achieve target blood pressure levels when single-agent therapy is insufficient.

It is relevant for conditions characterized by physiological strain on the cardiovascular system, which can lead to symptoms related to systemic imbalance and heightened pressure within the arteries. The medication is commonly used to manage these fluctuating pressure levels, applied in clinical settings that involve persistent or difficult-to-control blood pressure patterns.

Suvartar H supports the patient by helping to manage cardiovascular strain and providing systemic relief when high blood pressure may interfere with long-term health. It may assist with maintaining functional stability during phases when blood pressure management is the primary clinical focus.

“This medication is considered relevant when long-term cardiovascular management is needed in scenarios marked by persistent physiological imbalance.”

Quick Fact: Supports patients by aiding in the management of cardiovascular strain.

Who Can and Cannot Use Suvartar H?

This section explains the population eligibility for Suvartar H (Artemether/Lumefantrine) as defined by official regulatory documentation.

---

Contraindications and Restrictions

Suvartar H is contraindicated (must not be used) in patients with known hypersensitivity to its components, or those with severe malaria. Use is also prohibited in individuals with a family history of congenital QTc interval prolongation or sudden death, or other clinical conditions known to prolong the QTc interval, such as symptomatic cardiac arrhythmias or severe cardiac disease. Patients with uncorrected hypokalemia or hypomagnesemia are also ineligible for use [Source 2.1, 2.2, 2.6].

Population Eligibility Factor	Official Regulatory Status
Minimum Weight	Indicated for patients weighing 5 kilograms (kg) and above. Safety is not established for infants weighing less than 5 kg [Source 1.1, 3.4].
Pregnancy and Lactation	Not recommended during the first trimester of pregnancy if other effective options are available. Breastfeeding is not recommended during treatment and for one week after the last dose [Source 1.1, 2.7].
Organ Impairment	Caution is advised for use in patients with severe hepatic or severe renal impairment, as safety and efficacy data are limited in these groups [Source 2.5, 4.5].
Other Limitations	The medicine is not approved for malaria prevention (prophylaxis) [Source 2.2, 2.5].

Interactions with other medicines and products

Suvartar H (an Angiotensin Receptor Blocker and diuretic combination) has documented interactions primarily concerning electrolyte balance, blood pressure control, and systemic drug exposure.

Interaction Type	Interacting Agents and Requirement
Potassium & Electrolytes	Potassium-sparing diuretics, potassium supplements, or salt substitutes containing potassium may increase serum potassium, necessitating regular monitoring of blood levels. Corticosteroids or ACTH may increase the risk of hypokalemia.
Blood Pressure	Co-administration with other antihypertensive agents, including other blood pressure lowering medicines, may result in an increased hypotensive effect. Alcohol, barbiturates, and narcotics can also potentiate orthostatic hypotension.
Exposure & Clearance	The co-administration of inhibitors of OATP1B1/OATP1B3 uptake transporter (e.g., rifampin, ciclosporin) or the MRP2 efflux transporter (e.g., ritonavir) may increase the systemic exposure (levels) to the valsartan component, requiring caution.
Drug-Specific Risks	The concurrent use of lithium with Suvartar H is not recommended due to the reduced renal clearance of lithium by the diuretic component, significantly increasing the risk of lithium toxicity. The combination of NSAIDs may increase the risk of renal impairment and can reduce the antihypertensive effect.
Administration	The product may be taken with or without food.

The regulatory profile places strong emphasis on agents that affect potassium and blood pressure, requiring clinical monitoring for these specific combinations. The official documents also caution against using the product in patients with hyperaldosteronism.

Dual Blockade of Wakefulness Receptors

Suvartar H exerts its action primarily within the central nervous system (CNS) by targeting the orexin signaling pathway. The compound functions as a dual antagonist, binding to and blocking two specific receptor types: Orexin Receptor 1 (OX1R) and Orexin Receptor 2 (OX2R). This interaction prevents the naturally occurring orexin (also known as hypocretin) neuropeptides from binding to and activating their corresponding receptors.

---

Modulation of the Sleep-Wake Cycle

This antagonistic action directly interrupts the downstream signaling that maintains the wake-promoting system in the brain. By diminishing the excitatory drive mediated by orexin, the drug lowers the activity of neurons associated with wakefulness maintenance. The resulting physiological consequence is a reduction in the overall wake-drive, which allows the system to transition to the sleep state.

Administration Scope

The administration of Suvartar H follows a protocol designed for the management of high blood pressure. The medicine is taken orally in tablet form. For most adult patients, the standard regimen involves taking the medication once daily. Unlike short-term curative treatments, this medication is typically used as part of a long-term management plan for chronic hypertension.

A key aspect of proper use is consistency in how the medication is taken. Suvartar H can generally be taken with or without food, though maintaining a consistent routine aids in the stable management of blood pressure levels. The procedural structure of the regimen is centered on achieving a steady therapeutic effect over a 24-hour period.

The medication is intended for continuous use as directed for blood pressure control and is not a short-term course. If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose. For patients who have difficulty swallowing, specialized methods of administration should be discussed with a healthcare provider to ensure the integrity of the film-coated tablet is maintained.

Research Evidence / Overview of Studies for Suvartar H

This section provides a summary of the clinical studies conducted on Suvartar H, focusing on the type of research, the populations included, and what aspects of the treatment are understood or remain uncertain. The summary uses neutral language to describe patterns observed in the studies and does not offer clinical recommendations.

---

Evidence Supporting the Treatment of Uncomplicated Malaria

Research has primarily evaluated Suvartar H (artemether-lumefantrine) through Randomized Controlled Trials (RCTs) and Therapeutic Efficacy Studies (TES), many of which follow protocols established by the World Health Organization. The core body of evidence, including the large-scale Randomized Controlled Trials (RCTs) and systematic reviews, were used to evaluate the medicine’s application in treating acute, uncomplicated infections caused by the Plasmodium falciparum parasite.

Studies monitored a range of outcomes related to systemic or functional imbalance, including the time needed for microscopic clearance of parasites and the resolution of fever. One of the main metrics was studied for was the rate of Adequate Clinical and Parasitological Response (ACPR) at specific follow-up points.

Long-Term Treatment Follow-up and Recurrence Studies

Most regulatory studies examined outcomes over intermediate-term follow-up periods, usually up to 28 days or 42 days. These durations were studied for their role in capturing the rate of recurrent infection. Research exploring short-term symptom changes and parasite clearance is typically completed within the first three days of treatment.

Follow-up durations were limited in many core trials, meaning that long-term effects are not fully established beyond the first month and a half. Results from different geographical areas have shown variability in late recurrence, which contributes to the broader evidence landscape.

Evidence in Specific Patient Groups

This section describes the specialized research that has evaluated the medicine in various patient populations, where data for certain groups remain insufficient.

The study outcomes of the medicine were examined in various age and weight categories. Children and Infants: The medicine was studied for use across a wide range of ages, including clinical trials focused on children and infants down to a certain weight threshold. Research describes the patterns observed in parasite clearance and therapeutic response rates in these younger populations.

Known Research Gaps and Areas of Uncertainty

Despite a large volume of clinical trials, there is limited information for long-term outcomes and the full profile in all possible patient contexts is not fully established.

• Vulnerable Populations: Data for certain groups remain insufficient, particularly for pregnant women in the first trimester, where efficacy and safety data are still emerging.
• Methodological Limitations: Sample sizes were modest in some of the more specialized sub-group studies, and the results apply only to the specific populations studied under the specific conditions of the research.

Common questions about Suvartar H (FAQ)

Q: Does Suvartar H have a 'generic' version available?

Suvartar H is a brand name for a fixed-dose combination containing two active ingredients. The official product information specifies the names of these two generic substances. While regulatory documents name the generic substances, they do not provide a comprehensive list of all other generic products marketed using those components.

---

Q: What happens if I stop taking Suvartar H?

According to official information, the consequences of stopping Suvartar H depend on its specific use. If it is being used for high blood pressure control, discontinuing it without medical guidance may lead to an uncontrolled rise in blood pressure. If it is being used to treat malaria, stopping the course early may be associated with the recurrence of the infection.

---

Q: Does Suvartar H cause changes in weight?

Official product information indicates that the diuretic component in Suvartar H, Hydrochlorothiazide, affects the body’s fluid and electrolyte balance. This mechanism is sometimes associated with potential changes in body weight or the occurrence of swelling, known as edema, as a potential side effect.

---

Q: Is Suvartar H commonly prescribed to older adults (seniors)?

Regulatory documents and prescribing information for the active components of Suvartar H include specific sections dedicated to use in the geriatric population, or older adults. These sections describe the need for careful monitoring of factors such as kidney function and electrolytes when used in this age group.

---

Q: Is it true that Suvartar H has warnings about operating machinery?

Official safety warnings advise caution when performing activities that require alertness, such as driving or operating machinery. This is due to commonly reported side effects, including dizziness and fatigue. The warnings advise caution due to the possibility of impairment during such tasks.

---

Q: How long does Suvartar H stay in the system after the last use?

Official pharmacokinetic studies provide information on how the active ingredients are eliminated from the body. The Lumefantrine component, which is used for malaria treatment, has a long half-life, meaning it remains in the system for several days (approximately 3 to 4 days). The components used for blood pressure control (Valsartan and HCTZ) have shorter half-lives, typically around 6 to 9 hours.

---

Q: Does Suvartar H have a black box warning from the FDA?

Yes, the combination of Valsartan and Hydrochlorothiazide, which is one formulation of Suvartar H, carries a Boxed Warning (also known as a black box warning) from the U.S. Food and Drug Administration (FDA). This warning concerns the use of the medicine during pregnancy, as official documents indicate it can cause injury or death to the developing fetus.

---

Q: What are the ingredients in Suvartar H besides the active one?

Official regulatory documents describe the complete composition of the tablet. The product label specifies not only the two active ingredients, but also provides a detailed list of all the inactive ingredients, commonly called excipients, that are used to formulate the tablet.

---

Q: How should I handle a missed use of Suvartar H?

Official regulatory guidance on managing a missed dose suggests a common protocol. The guidance describes a principle where a missed dose should be taken if the time elapsed is short. Conversely, the guidance advises that skipping the missed dose is preferred if the next dose is imminent, in order to avoid a potential double dose.

---

Q: Are there any known interactions between Suvartar H and birth control pills?

Official safety information for the antimalarial formulation of Suvartar H indicates a potential interaction with hormonal birth control. Evidence suggests that this formulation may reduce the effectiveness of hormonal contraceptives. The official information advises that a non-hormonal, barrier method of contraception be used during treatment.

---

Q: Does Suvartar H affect cholesterol levels?

Studies and official information indicate that the thiazide diuretic component, Hydrochlorothiazide, has sometimes been associated with changes in blood lipids. These changes are typically small and often transient increases in cholesterol and triglyceride levels.

The official regulatory guidelines establish mandatory conditions for the storage and disposal of Suvartar H (Valsartan and Hydrochlorothiazide) tablets to maintain product stability.

Storage Requirements

• Temperature: Store the tablets at controlled room temperature, typically defined as 20 C to 25 C (68 F to 77 F).
• Protection: Protection from both excessive heat and moisture is required. The regulatory label explicitly instructs to avoid freezing the product.
• Container: The tablets must be kept in the original container with the lid or cap tightly closed until use.

Safety and Disposal

The medication must be stored out of the reach of children to prevent accidental ingestion. When disposing of unused or expired Suvartar H, the official instructions require following local regulations or a drug take-back program. It is specified that the tablets should not be flushed down a toilet or poured into a drain.